TY - JOUR
T1 - Grand rounds in gastroenterology from Baylor College of Medicine - A 42-year-old Cushingoid man with a bleeding duodenal ulcer
AU - Julapalli, Venu
AU - Shafi, Mehnaz
AU - Schwartz, Jim
AU - Goodgame, Richard
PY - 2004
Y1 - 2004
N2 - Although our patient had a rare tumor, the differential diagnosis illustrates the interesting biologic spectrum of neuroendocrine tumors of the pancreas. These tumors can occur sporadically in patients without a family history. However, one tumor can produce multiple hormones. In this situation, the tumors may mimic the MEN syndromes, prompting a search for second or third tumors. The presence of MEN-1 syndrome should be investigated in all patients with concomitant Zollinger-Ellison syndrome and Cushing's syndrome. Only a full hormonal and anatomic evaluation can clarify the clinical alternatives: one tumor producing multiple hormones vs multiple endocrine tumors. Gastrinomas that produce ACTH are much more biologically aggressive than simple gastrinomas. Therapy is not based on prospective randomized clinical trials but on appreciating the unique combination of hormone production and tumor spread. Treatment decisions first involve symptom control, then a multidisciplinary approach that may include surgical debulking, somatostatin analog therapy, and chemotherapy.
AB - Although our patient had a rare tumor, the differential diagnosis illustrates the interesting biologic spectrum of neuroendocrine tumors of the pancreas. These tumors can occur sporadically in patients without a family history. However, one tumor can produce multiple hormones. In this situation, the tumors may mimic the MEN syndromes, prompting a search for second or third tumors. The presence of MEN-1 syndrome should be investigated in all patients with concomitant Zollinger-Ellison syndrome and Cushing's syndrome. Only a full hormonal and anatomic evaluation can clarify the clinical alternatives: one tumor producing multiple hormones vs multiple endocrine tumors. Gastrinomas that produce ACTH are much more biologically aggressive than simple gastrinomas. Therapy is not based on prospective randomized clinical trials but on appreciating the unique combination of hormone production and tumor spread. Treatment decisions first involve symptom control, then a multidisciplinary approach that may include surgical debulking, somatostatin analog therapy, and chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=25144490670&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=25144490670&partnerID=8YFLogxK
M3 - Article
C2 - 15266242
AN - SCOPUS:25144490670
SN - 1531-0132
VL - 6
JO - MedGenMed Medscape General Medicine
JF - MedGenMed Medscape General Medicine
IS - 2
ER -